Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

In England, about 600 people will benefit from the daily pill that helps treat lung cancer as it becomes routinely available on the NHS.

Daily pill on NHS offers new hope for hundreds with lung cancer - Osimertinib, also known as Tagrisso and made by AstraZeneca ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...